Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell

Clinical Trial Summary

The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.

See also
Status	Clinical Trial	Phase
Completed	`NCT03163667` - CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)	Phase 2
Withdrawn	`NCT02307474` - A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer	N/A
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Completed	`NCT00101114` - Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer	Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Recruiting	`NCT05363631` - Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab	Phase 1/Phase 2
Terminated	`NCT01198158` - Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy	Phase 3
Completed	`NCT00378703` - Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer	Phase 2
Recruiting	`NCT06138496` - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC	Phase 2
Recruiting	`NCT06088134` - Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Recruiting	`NCT06049576` - Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma	Phase 1
Active, not recruiting	`NCT01038778` - Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer	Phase 1/Phase 2
Recruiting	`NCT05536141` - A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors	Phase 1
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT01243359` - Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies	Phase 1
Terminated	`NCT00098618` - Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer	Phase 2
Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
Recruiting	`NCT06052852` - Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies	Phase 1/Phase 2
Completed	`NCT03680521` - Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma	Phase 2
Recruiting	`NCT06195150` - Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer

NCT number	NCT02923531
Study type	Interventional
Source	X4 Pharmaceuticals
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	December 7, 2016
Completion date	August 8, 2018

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms